Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
42 participants
OBSERVATIONAL
2022-07-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR
NCT05205291
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
NCT00129675
Identification of a Biomarker Predictive of Evolution of Parkinson Disease
NCT03230526
PET Study of Non-Motor Symptoms of Parkinson Disease
NCT01565473
Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET
NCT02319382
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study visits will take place in London. There are three locations on Hammersmith hospital campus, that are located near to each other. The NIHR Imperial Clinical Research Facility and Invicro London for clinical and MRI and PET assessments, and Imperial Healthcare Nuclear Medicine Department for the SPECT scan.
Participants will attend 5 visits in a 3 month period. These visits include an initial consent and assessment visit where some blood samples will also be taken. The second visit involves a PET scan with the tracer DASB along with an MRI scan. The third visit involves two PET scans one in the morning, with CIMBI tracer, an injection of Dexamphetamine, and then a second with CIMBI tracer to make a comparison. The fourth visit involves a SPECT scan, and the fifth visit is optional and would be for a lumbar puncture visit. Each visit will last around 6 hours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SNCA (Alpha-synuclein gene)
PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
Positron Emission Tomography (PET) scan using CIMBI-36 tracer
This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
Magnetic Resonance Imaging (MRI) Scan
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
Positron Emission Tomography (PET) scan using DASB tracer
To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
FP-CIT Single-photon Emission Computed Tomography (SPECT) scan
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
Lumbar puncture
A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
Idiopathic Parkinson's Disease
PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
Positron Emission Tomography (PET) scan using CIMBI-36 tracer
This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
Magnetic Resonance Imaging (MRI) Scan
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
Positron Emission Tomography (PET) scan using DASB tracer
To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
FP-CIT Single-photon Emission Computed Tomography (SPECT) scan
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
Lumbar puncture
A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Positron Emission Tomography (PET) scan using CIMBI-36 tracer
This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
Magnetic Resonance Imaging (MRI) Scan
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
Positron Emission Tomography (PET) scan using DASB tracer
To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
FP-CIT Single-photon Emission Computed Tomography (SPECT) scan
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
Lumbar puncture
A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and females, age 25-85 years, inclusive;
* Women of child-bearing potential must use protocol-defined contraceptive measures and must have a negative β-hCG test at screening. For sexually active subjects (except females of non-childbearing potential-e.g., at least 2 years postmenopausal or surgically sterile), condoms should be used in addition to other birth control methods for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. These patients must be willing to remain on their current form of contraception for the duration of the study. All male subjects must agree to refrain from donating sperm for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. Sexually active male subjects must agree to use condoms to protect their partners from becoming pregnant for the duration of the study and for 3 months after the last administration of PET or SPECT ligands (i.e. for 15 consecutive months following baseline PET and SPECT scans); agree to ensure that they and their partners are routinely using a medically approved contraceptive method. It is important that male subjects not impregnate others for the duration of the study and for 3 months after the last administration of PET or SPECT ligands;
* Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures;
* Adequate visual and auditory acuity to complete the psychological testing;
* In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.
Exclusion Criteria
* Subjects taking serotonin acting drugs such as antidepressants (i.e. tricyclic or selective serotonin reuptake inhibitors etc.);
* Pregnancy or breastfeeding or intent to become pregnant in the next 18 months;
* Subjects with current or a recent history of drug or alcohol abuse/dependence;
* Subjects who have other neurological disorders and known intracranial co-morbidities such as stroke, hemorrhage, space-occupying lesions;
* Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgment of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results;
* History of suicidal behaviour or active suicidal ideation;
* Within 1 year prior to screen or between screen and baseline (Day -1), any of the following: myocardial infarction; hospitalization for congestive heart failure; hospitalization for, or symptoms of, unstable angina; or syncope not related to PD;
* History or presence of renal disease or impaired renal function;
* Clinically important infection (e.g., chronic, persistent, or acute infection) within 30 days prior to screen or between screen and baseline (Day -1);
* History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma of the skin;
* Clinically significant blood clotting or bleeding disorder, including clinically significant abnormal findings in laboratory assessments of coagulation or hematology;
* Use of antipsychotic medication within 3 months prior to screen or between screen and baseline (Day -1);
* Use of any anticoagulant within 30 days prior to baseline and follow-up PET scans;
* Use of any oral corticosteroid within 30 days prior to baseline and follow-up PET scans;
* Use of metoclopramide within 30 days prior to baseline and follow-up (Day -1);
* Use of any thyroid medication within 30 days prior to baseline and follow-up (Day -1);
* Regular use (e.g., taken \> 3 days/week) of narcotic pain medications within 30 days prior to baseline and follow-up (Day -1);
* Presence of any of the following MRI contraindications: pacemaker; cardiac defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart valve; recent coronary or carotid stent; ear implant; CSF shunt; other implanted medical device (e.g., Swan-Ganz catheter, insulin pump); or metal fragments or foreign objects in the eyes, skin, or body;
* Negative modified Allen test in both hands, unless the brachial artery is used for arterial cannulation;
* Claustrophobia or history of back pain that makes prolonged laying on the PET or MRI scanner intolerable;
* History of severe skin allergy;
* Patients who had previous surgery for PD (including but not limited to deep brain stimulation \[DBS\] or cell transplantation);
* Patients who are treated with duodopa or apomorphine;
* Initiation or change in pharmacologic therapy for symptoms of PD within 30 days prior to screen or between screen and baseline and follow-up (Day -1).
* GDS score greater than or equal to 10 (GDS score of 5 - 9 requires Investigator discretion to enter study).
* STAI Form Y-1 greater than or equal to 54 requires Investigator discretion to enter study.
25 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Exeter
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marios M Politis, Professor
Role: PRINCIPAL_INVESTIGATOR
University of Exeter
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of Exeter
Exeter, Devon, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
University of Exeter brief project information webpage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-21-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.